Home › Kidney Cancer (Renal Cell Carcinoma) › NCT06601296

Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer

STING Agonist and Personalized Ultra-fractionated Stereotactic Adaptive Radiotherapy in Combination With Checkpoint Inhibition for Patients With Metastatic Kidney Cancer.

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Patients must have metastatic ccRCC.
* Patients must have oligoprogression defined as progression in ≤5 lesions.
* All oligoprogression lesions must be suitable for radiation.
* Patients must have at least one site of disease that can be safely injected with IMSA101.
* Karnofsky Performance Status (KPS) of at least 50%.
* Age ≥ 18 years.
* Patients must have adequate organ and marrow function within 14 days prior to study entry.
* All IMDC risk categories are allowed.

Exclusion Criteria:

* Patients with progressive ultracentral/central chest lesions will be excluded

About the study

To evaluate the impact of combining innate immune system activation (with IMSA101) with antigen release (through SAbR/PULSAR) on limited progressing lesions during ongoing adaptive immune system activation (with maintenance Nivo).

What is being tested

• IMSA101 (drug)

Sponsor: University of Texas Southwestern Medical Center · Participants: 15 · Started: Apr 1, 2025

Contact the study team

• SARAH NEUFELD, MANAGER OF CLINICAL RESEARCH, MS, MBA · Phone: 214 648 1836
• RAQUIBUL HANNAN, MD, PhD. · Phone: 214 645 7696

Official record on ClinicalTrials.gov — NCT06601296

Locations in the U.S.

Conditions

• Kidney Cancer (Renal Cell Carcinoma)
• Metastatic Cancer
• Cancer (all types)
• Animal Bites

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.